AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. OSTX
  4. [D] OS Therapies Incorporated SEC Filing

[D] OS Therapies Incorporated SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
D

Filing content is currently unavailable.

Source:

Stock OSTX logo
OS THERAPIES INCORPORATED

NYSE:OSTX

OSTX Rankings

#7591 Ranked by Market Cap
N/A Ranked by Dividends

OSTX Latest News

Aug 7, 2025
OS Therapies Announces Statistically Significant Positive Interim 2-Year Overall Survival Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
Aug 7, 2025
OS Therapies Receives Positive Feedback from UK MHRA Scientific Advice Meeting and Submits Innovative Licensing and Access Pathway (ILAP) Request for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
Jul 14, 2025
OS Therapies Closes $4.2 Million in Warrant Exercise Inducement and Exchange Offer
Jul 10, 2025
OS Therapies Provides Clinical & Global Regulatory Updates
Jul 3, 2025
OS Therapies Granted End of Phase 2 Meeting by US FDA for OST-HER2 Program in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

OSTX Latest SEC Filings

Aug 8, 2025
[S-3] OS Therapies Incorporated Shelf Registration Statement
Aug 4, 2025
[S-1] OS Therapies Incorporated Files IPO Registration Statement
Jul 14, 2025
[8-K] OS Therapies Incorporated Reports Material Event
Jun 27, 2025
[8-K] OS Therapies Incorporated Reports Material Event
Jun 24, 2025
[8-K] OS Therapies Incorporated Reports Material Event

OSTX Stock Data

59.48M
18.72M
33.38%
1.39%
1.54%
Biotechnology
Pharmaceutical Preparations
United States
ROCKVILLE